Table 2B.
Characteristics of urine data participants by usage status
| Non-users n=180 (94%) Mean (SD) |
Users n=11 (6%) Mean (SD) |
p | |
|---|---|---|---|
| Age (years) | 70.55 (10.24) | 63.55 (8.03) | 0.023 |
| Years on ADT | 3.00 (2.91) | 2.59 (4.11) | 0.046 |
| Type of ADT | 0.856 | ||
| Eligard (Leuprolide) | 27 (15%) | 3 (27%) | |
| Firmagon (Degarelix) | 10 (6%) | 0 | |
| Lupron (Leuprolide) | 69 (38%) | 3 (27%) | |
| Suprefact (Buserelin) | 2 (1%) | 0 | |
| Trelstar (Triptorelin) | 9 (5%) | 1 (9%) | |
| Zoladex (Goserelin) | 60 (33%) | 4 (36%) | |
| Casodex (Biclutamide) | 3 (2%) | 0 | |
| Most recent testosterone level (nmol/L) | 0.86 (1.34) | 0.41 (0.24) | 0.016 |
ADT: androgen-deprivation therapy; SD: standard deviation.